Alnylam Pharmaceuticals Inc., a leading RNAi therapeutics company, has announced the release of its 2024 Corporate Responsibility Report. The report highlights Alnylam's efforts and progress across its six corporate responsibility pillars, including environmental impact, patient access, health equity, and company culture. Key disclosures in the report include independently verified multiyear data on the company's greenhouse gas emissions (Scope 1, 2, and 3) as well as data on energy, water, and waste management. The report also emphasizes the use of 100% renewable energy at Alnylam's Norton and Alewife sites. Additionally, the company has made strides in its global Patient Access Philosophy and health equity initiatives, partnering with social entrepreneurs and non-profit organizations to address health inequalities. Alnylam also reported an ongoing focus on employee inclusion and development, with 88% of employees feeling accepted and treated fairly.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.